IM Cannabis (IMCC) Competitors $2.02 -0.05 (-2.42%) Closing price 03:59 PM EasternExtended Trading$2.10 +0.08 (+3.91%) As of 04:48 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock IMCC vs. GRCE, VRCA, BCAB, JSPR, GBIO, ANVS, ELUT, MRSN, XFOR, and PLURShould you be buying IM Cannabis stock or one of its competitors? The main competitors of IM Cannabis include Grace Therapeutics (GRCE), Verrica Pharmaceuticals (VRCA), BioAtla (BCAB), Jasper Therapeutics (JSPR), Generation Bio (GBIO), Annovis Bio (ANVS), Elutia (ELUT), Mersana Therapeutics (MRSN), X4 Pharmaceuticals (XFOR), and Pluri (PLUR). These companies are all part of the "pharmaceutical products" industry. IM Cannabis vs. Its Competitors Grace Therapeutics Verrica Pharmaceuticals BioAtla Jasper Therapeutics Generation Bio Annovis Bio Elutia Mersana Therapeutics X4 Pharmaceuticals Pluri Grace Therapeutics (NASDAQ:GRCE) and IM Cannabis (NASDAQ:IMCC) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, earnings, dividends, institutional ownership, analyst recommendations, risk, media sentiment and profitability. Do insiders and institutionals believe in GRCE or IMCC? 6.1% of Grace Therapeutics shares are owned by institutional investors. Comparatively, 7.7% of IM Cannabis shares are owned by institutional investors. 11.1% of Grace Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term. Does the media prefer GRCE or IMCC? In the previous week, IM Cannabis' average media sentiment score of 0.00 beat Grace Therapeutics' score of -1.00 indicating that IM Cannabis is being referred to more favorably in the news media. Company Overall Sentiment Grace Therapeutics Negative IM Cannabis Neutral Which has better earnings & valuation, GRCE or IMCC? IM Cannabis has higher revenue and earnings than Grace Therapeutics. IM Cannabis is trading at a lower price-to-earnings ratio than Grace Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioGrace TherapeuticsN/AN/A-$9.57M-$0.86-3.51IM Cannabis$39.44M0.27-$7.72M-$0.54-3.74 Is GRCE or IMCC more profitable? Grace Therapeutics has a net margin of 0.00% compared to IM Cannabis' net margin of -4.19%. Grace Therapeutics' return on equity of -20.36% beat IM Cannabis' return on equity.Company Net Margins Return on Equity Return on Assets Grace TherapeuticsN/A -20.36% -18.09% IM Cannabis -4.19%-59.80%-5.15% Which has more risk & volatility, GRCE or IMCC? Grace Therapeutics has a beta of 1, meaning that its stock price has a similar volatility profile to the S&P 500.Comparatively, IM Cannabis has a beta of 2.13, meaning that its stock price is 113% more volatile than the S&P 500. Do analysts rate GRCE or IMCC? Grace Therapeutics presently has a consensus target price of $12.00, indicating a potential upside of 297.35%. Given Grace Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Grace Therapeutics is more favorable than IM Cannabis.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Grace Therapeutics 1 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.33IM Cannabis 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 SummaryGrace Therapeutics and IM Cannabis tied by winning 7 of the 14 factors compared between the two stocks. Get IM Cannabis News Delivered to You Automatically Sign up to receive the latest news and ratings for IMCC and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding IMCC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart IMCC vs. The Competition Export to ExcelMetricIM CannabisMED PRODUCTS IndustryMedical SectorNASDAQ ExchangeMarket Cap$10.86M$10.93B$6.12B$10.65BDividend YieldN/A1.86%5.69%4.73%P/E Ratio-3.7422.1785.6126.85Price / Sales0.2728.70612.81135.18Price / CashN/A25.4437.7861.77Price / Book1.963.4413.256.70Net Income-$7.72M$210.63M$3.30B$276.44M7 Day Performance5.21%1.69%4.70%3.13%1 Month Performance2.54%1.31%8.43%10.21%1 Year Performance-9.82%-5.72%88.01%40.35% IM Cannabis Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)IMCCIM CannabisN/A$2.02-2.4%N/A-8.8%$10.86M$39.44M-3.74340GRCEGrace Therapeutics2.0595 of 5 stars$2.98+0.3%$12.00+302.7%N/A$41.07MN/A0.00N/AShort Interest ↑VRCAVerrica Pharmaceuticals3.8059 of 5 stars$4.31+0.2%$80.00+1,756.1%-64.2%$40.62M$7.57M-0.5240News CoverageBCABBioAtla0.7144 of 5 stars$0.69-0.5%N/A-62.7%$40.61M$11M0.0060Gap UpJSPRJasper Therapeutics3.237 of 5 stars$2.38-4.4%$25.63+976.7%-85.1%$40.47MN/A0.0020GBIOGeneration Bio3.5941 of 5 stars$6.12+2.3%$10.67+74.3%-74.7%$40.28M$19.89M-0.57150ANVSAnnovis Bio2.44 of 5 stars$2.06+1.0%$17.33+741.4%-73.3%$39.75MN/A0.003ELUTElutia3.2355 of 5 stars$0.89-4.3%$7.00+686.3%-76.7%$39.43M$24.38M0.00180MRSNMersana Therapeutics4.0076 of 5 stars$7.76-0.4%$56.60+629.4%-84.5%$38.88M$40.50M-0.53150XFORX4 Pharmaceuticals3.9702 of 5 stars$3.42+2.1%$34.17+899.0%-81.9%$38.22M$2.56M0.0080PLURPluri1.7409 of 5 stars$4.48-2.8%$12.00+167.9%-17.0%$37.60M$1.34M-0.87150 Related Companies and Tools Related Companies GRCE Competitors VRCA Competitors BCAB Competitors JSPR Competitors GBIO Competitors ANVS Competitors ELUT Competitors MRSN Competitors XFOR Competitors PLUR Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:IMCC) was last updated on 10/7/2025 by MarketBeat.com Staff From Our PartnersBitcoin grabs headlines, but smart money likes this tokenBitcoin grabs headlines, but smart money likes this token My research team has identified the token positio...Crypto 101 Media | SponsoredMagnificent 7 being replaced by the “Hidden 7”?BULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | SponsoredAn $8 trillion-dollar discovery 17,000 ft underwater A strange rock pulled from the ocean floor may hold the key to a $16 trillion resource boom. Inside it: materi...Porter & Company | SponsoredCapital Gains Tax Strategies for SeniorsCapital gains taxes can take a bite out of your retirement income—unless you have a smart strategy. From holdi...SmartAsset | Sponsored$100 Trillion “AI Metal” Found in American Ghost TownJeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could...Brownstone Research | SponsoredURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredThe Tiny Stock Set to Soar with Musk's AI AmbitionsThe Tiny Stock Set to Soar with Musk's AI Ambitions While Musk builds one of the most ambitious AI empires ...Behind the Markets | Sponsored$3,600 gold is nice ... but here’s what most gold bugs are missingGold just surged past $3,600, but Weiss Ratings expert Sean Brodrick says the real upside is in select gold st...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding IM Cannabis Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share IM Cannabis With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
